PTO/SB/08a (03-09)

Approved for use through 04/30/2009, OMB 0651-0031 S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

11/30/2009

Considered

		iark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to re	spond to a collection of informati	on unless it contains a valid OMB control number
Substitute for form 1449/PTO		nplete if Known
	Application Number	10/576,121
INFORMATION DISCLOSURE	Filing Date	January 22, 2007
	First Named Inventor	Jerome B. Zeldis
STATEMENT BY APPLICANT	Art Unit	1617
(Use as many sheets as necessary)	Examiner Name	Manu M. Manohar
Sheet 1 of 3	Attorney Docket Number	9516-314-999

				DOCUMENTS	
Examiner Initials*	No.	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 2002/0045643	04-18-2002	Muller et al.	
	A2	us- 2002/0137755	09-26-2002	Bilodeau et al.	
		us-			1

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ⁵ "Number ⁴ " Kind Code ⁵ (if known)	MM-DD-YYYY	7,	Or Relevant Figures Appear	T ⁶
	B1	WO 2004/041190	05-21-2004	CELGENE CORPORATION		
	B2	WO 2004/041181	05-21-2004	CELGENE CORPORATION		П
	B3	WO 00/02564	01-20-2000	THE UNIVERSITY OF SYDNEY		
	B4	WO 03/014315	02-20-2003	THE CHILDREN'S MEDICAL CE	NTER CORP	
	B5	WO 02/058730		ALLERGAN SALES, INC.		
	В6	WO 2004/027027	04-01-2004	TRUSTEES OF THE UNIV. OF F	ENNSYLVANIA	

EXAMPLET intial reference considered, whether or not clasters is nonformance with MEEP 6/60 Date line through catation if not in conformance and not considered include copy of this form with next communication to applicate. "Applicated unique catation designation number (optional) or USPTO Patient Documents at https://www.examplet.org/ is well as the following of the second of the patient of the pa

/Sarah Pihonak/

Signatura

Infanciation is statisfied.
This collection of this collection of the collection of

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (03-09)

Approved for use through 04/30/2009. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number							
Substitute for form 1449/PTO		Complete if Known					
	Application Number	10/576,121					
INFORMATION DISCLO	SIIDE Filing Date	January 22, 2007					
	First Named Inven	tor Jerome B. Zeldis					
STATEMENT BY APPL		1617					
(Use as many sheets as necessar	LAGITING INGING	Manu M. Manohar					
Sheet 2 of 3	Attorney Docket N	umber 9516-314-999					

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	-	US-	_		
		00-			
		us-		-	
		us-			
	_	us-	+		

		FORFIG	N PATENT DOCU	IMENTS		\neg
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	B7	WO 02/064083	08-22-2002	THE CHILDREN'S MEDICAL CE	NTER CORP	

Signature	/Sarah Pihonak/		Considered	11/30/2	009
EXAMINER	Initial if reference considered, whether or not citation is in conformance with MPE	EP 609. Dra	w fine through o	citation if not it	n conformance and not
considered. I	include copy of this form with next communication to applicant. Applicant's unique	as citation d	esignation num	her (optional).	2 See Kinds Codes of

Considered include copy or the form with next commonwation to applicate. Applicates unique calculation designation frames (opticities) as See Kinst Codes.

USPTO Patter Documents at <u>www.tsstpic.sex</u> or MPEP 910.4. **Enter Office that issued the document, by the two-teller code (WIPO Standard STAS) **For Japanese patent documents, the indication of the year of the region of the Emperor must proceed serial number of the patent document. **Yind of document by the appropriate symbols as indicated on the document under WIPO Standard STAG in Standar Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including githering preparing and submitting the completed application from the USFTO. This will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this bunder, should be sent to the Circle (Tennation Officer, U.S. Patient and Trademark Office, P.O. 560 1.456, Austrandis, AV 22315-1450. D. DO NT SEND FEES OR COMMETTED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Une	der the Paperwork Red	uction A	t of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number.	
Substitute for form 1449/PTO			Complete if Known			
				Application Number	10/576,121	
			CLOSURE	Filing Date	January 22, 2007	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Jerome B. Zeldis	
	(Use as many she	ofs as n	ecessary)	Art Unit	1617	
	, and an interior	43 //		Examiner Name	Manu M. Manohar	
Sheet	3	of	3	Attorney Docket Number	9516-314-999	

	0.1	NON PATENT LITERATURE DOCUMENTS	_
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	Supplementary European Search Report	
	C2	SPAIDE et al., Combined Photodynamic Therapy with Verteporfin and Intravitreal Triancinolene Acetonide for Choroidal Neovascularization, Ophthalmology, Vol. 110, No. 8, 1 Aug 2003, p. 1517-1525	
	СЗ	HUNT et al., Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes, Immunopharmacology Vol. 41, No. 1, 1 Jan 1999, p. 31-44	
	C4	KRUGER et al., Short-term Oral Pentoxifylline Use Increases Choroldal Blood Flow in Patients With Age-related Macular Degeneration, Arch. Ophthalmol., Vol. 116, No. 1, 1 Jan 1998, p. 27-30	
	C5	CIULLA et al., Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy, Exp. Opin. Invest. Drugs, Vol. 8, No. 12, 1 Dec 1999, p. 2173-2182	
	C6	FINE et al., Age-related Macular Degeneration, New England Journal of Medicine, Vol. 342, No. 7, 17 Feb 2000, p. 483-492	
	C7	AMBRUS et al., Study of Antiangiogenic Agents with Possible Therapeutic Applications in Neoplastic Disorders and Macular Degeneration, Journal of Medicine, Vol. 31, No. 5-6, 1 Jan 2000, p. 278-282	
	C8	RICHARDSON et al., Thalidomide in multiple myeloma, Biomed Pharmacother, Vol. 56, No. 3, May 2002, p. 115-128	
	C9	BRIEGEL et al., Immunomodulation in Septic Shock: Hydrocortisone Differentially Regulates Cytokine Responses, Journal of the American Soc. of Nephrology, Vol. 12, Suppl. 17, Feb 2001. p. \$70-\$74	

Examiner Signature	/Sarah Pihonak/	Date Considered	11/30/2009	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

consistence include copy or was some with field communication to application.

The collection of information is entirely to the control of th